S&P 500   5,115.27 (+0.37%)
DOW   38,996.43 (+0.00%)
QQQ   443.05 (+0.92%)
AAPL   178.20 (-1.41%)
MSFT   413.01 (-0.15%)
META   499.28 (+1.87%)
GOOGL   137.78 (-0.49%)
AMZN   177.94 (+0.67%)
TSLA   200.88 (-0.50%)
NVDA   819.31 (+3.56%)
NIO   5.84 (+1.57%)
AMD   198.98 (+3.35%)
BABA   74.89 (+1.16%)
T   16.96 (+0.18%)
F   12.50 (+0.48%)
MU   95.60 (+5.51%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.41 (-0.15%)
AMC   4.42 (+2.31%)
PFE   26.56 (+0.00%)
PYPL   60.64 (+0.50%)
XOM   106.18 (+1.59%)
S&P 500   5,115.27 (+0.37%)
DOW   38,996.43 (+0.00%)
QQQ   443.05 (+0.92%)
AAPL   178.20 (-1.41%)
MSFT   413.01 (-0.15%)
META   499.28 (+1.87%)
GOOGL   137.78 (-0.49%)
AMZN   177.94 (+0.67%)
TSLA   200.88 (-0.50%)
NVDA   819.31 (+3.56%)
NIO   5.84 (+1.57%)
AMD   198.98 (+3.35%)
BABA   74.89 (+1.16%)
T   16.96 (+0.18%)
F   12.50 (+0.48%)
MU   95.60 (+5.51%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.41 (-0.15%)
AMC   4.42 (+2.31%)
PFE   26.56 (+0.00%)
PYPL   60.64 (+0.50%)
XOM   106.18 (+1.59%)
S&P 500   5,115.27 (+0.37%)
DOW   38,996.43 (+0.00%)
QQQ   443.05 (+0.92%)
AAPL   178.20 (-1.41%)
MSFT   413.01 (-0.15%)
META   499.28 (+1.87%)
GOOGL   137.78 (-0.49%)
AMZN   177.94 (+0.67%)
TSLA   200.88 (-0.50%)
NVDA   819.31 (+3.56%)
NIO   5.84 (+1.57%)
AMD   198.98 (+3.35%)
BABA   74.89 (+1.16%)
T   16.96 (+0.18%)
F   12.50 (+0.48%)
MU   95.60 (+5.51%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.41 (-0.15%)
AMC   4.42 (+2.31%)
PFE   26.56 (+0.00%)
PYPL   60.64 (+0.50%)
XOM   106.18 (+1.59%)
S&P 500   5,115.27 (+0.37%)
DOW   38,996.43 (+0.00%)
QQQ   443.05 (+0.92%)
AAPL   178.20 (-1.41%)
MSFT   413.01 (-0.15%)
META   499.28 (+1.87%)
GOOGL   137.78 (-0.49%)
AMZN   177.94 (+0.67%)
TSLA   200.88 (-0.50%)
NVDA   819.31 (+3.56%)
NIO   5.84 (+1.57%)
AMD   198.98 (+3.35%)
BABA   74.89 (+1.16%)
T   16.96 (+0.18%)
F   12.50 (+0.48%)
MU   95.60 (+5.51%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.41 (-0.15%)
AMC   4.42 (+2.31%)
PFE   26.56 (+0.00%)
PYPL   60.64 (+0.50%)
XOM   106.18 (+1.59%)

Sage Therapeutics (SAGE) Stock Price, News & Analysis

$22.11
+0.63 (+2.93%)
(As of 11:22 AM ET)
Today's Range
$21.42
$22.16
50-Day Range
$21.13
$26.95
52-Week Range
$16.51
$59.99
Volume
123,871 shs
Average Volume
1.01 million shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.71

Sage Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
88.6% Upside
$41.71 Price Target
Short Interest
Bearish
18.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.51
Upright™ Environmental Score
News Sentiment
0.78mentions of Sage Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.29) to ($4.57) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.28 out of 5 stars

Medical Sector

148th out of 957 stocks

Pharmaceutical Preparations Industry

59th out of 440 stocks


SAGE stock logo

About Sage Therapeutics Stock (NASDAQ:SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Stock Price History

SAGE Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
SAGE Jan 2025 30.000 put
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
SAGE Therapeutics, Inc. Q4 Loss decreases, beats estimates
Sage Therapeutics Q4 2023 Earnings Preview
Sage Therapeutics Inc
Sage Therapeutics moves HQ, downsizes office space
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/01/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SAGE
Employees
689
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.71
High Stock Price Target
$294.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+94.2%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
16 Analysts

Profitability

Net Income
$-541,490,000.00
Net Margins
-626.32%
Pretax Margin
-626.33%

Debt

Sales & Book Value

Annual Sales
$86.46 million
Book Value
$13.30 per share

Miscellaneous

Free Float
56,801,000
Market Cap
$1.29 billion
Optionable
Optionable
Beta
0.93

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report














SAGE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 14 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price target for 2024?

16 analysts have issued 1-year price targets for Sage Therapeutics' shares. Their SAGE share price targets range from $20.00 to $294.00. On average, they expect the company's share price to reach $41.71 in the next year. This suggests a possible upside of 88.6% from the stock's current price.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2024?

Sage Therapeutics' stock was trading at $21.67 on January 1st, 2024. Since then, SAGE shares have increased by 2.0% and is now trading at $22.11.
View the best growth stocks for 2024 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our SAGE earnings forecast
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) released its quarterly earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.28) by $0.73. The biopharmaceutical company earned $77.97 million during the quarter, compared to analysts' expectations of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative trailing twelve-month return on equity of 54.41%. The company's quarterly revenue was up 2621.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.47) earnings per share.

What ETFs hold Sage Therapeutics' stock?
What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.86%), RTW Investments LP (8.66%), Palo Alto Investors LP (1.65%), Dimensional Fund Advisors LP (1.61%), Northern Trust Corp (0.90%) and Price T Rowe Associates Inc. MD (0.80%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAGE) was last updated on 3/1/2024 by MarketBeat.com Staff